References
- Andersson TB, Kanebratt KP, Kenna JG. (2012). The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909–20
- Asha S, Vidyavathi M. (2010). Role of human liver microsomes in in vitro metabolism of drugs—a review. Appl Biochem Biotechnol 160:1699–722
- Boddy AV, Yule SM. (2000). Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38:291–304
- Brown RP, Delp MD, Lindstedt SL, et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–84
- Chen CS, Jounaidi Y, Waxman DJ. (2005). Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos 33:1261–7
- Cheng Y, Ma L, Chang SY, et al. (2016). Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos 44:1372–80
- De Bruyn T, Chatterjee S, Fattah S, et al. (2013). Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 9:589–616
- Esch EW, Bahinski A, Huh D. (2015). Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 14:248–60
- Gao G, Law FC. (2009). Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA. Drug Metab Dispos 37:884–91
- Huh D, Torisawa YS, Hamilton GA, et al. (2012). Microengineered physiological biomimicry: organs-on-chips. Lab Chip 12:2156–64
- Lee J, Kim SH, Kim YC, et al. (2013). Fabrication and characterization of microfluidic liver-on-a-chip using microsomal enzymes. Enzyme Microb Technol 53:159–64
- Lu H, Chan KK. (2006). Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat. Cancer Chemother Pharmacol 58:532–9
- Nelson AC, Huang W, Moody DE. (2001). Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. Drug Metab Dispos 29:319–25
- Prot JM, Videau O, Brochot C, et al. (2011). A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int J Pharm 408:67–75
- Ram N, Kalász H, Adeghate E, et al. (2012). Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations). Curr Med Chem 19:5683–704
- Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140–8
- Sahi J, Grepper S, Smith C. (2010). Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. Curr Drug Discov Technol 7:188–98
- Saussele T. (2014). 50 years of cytochrome P450. Drug metabolism—from past to present. Med Monatsschr Pharm 37:295–8
- Venkatesh S, Lipper RA. (2000). Role of the development scientist in compound lead selection and optimization. J Pharm Sci 89:145–54
- Yang H, Zheng Y, Zhao B, et al. (2013). Encapsulation of liver microsomes into a thermosensitive hydrogel for characterization of drug metabolism and toxicity. Biomaterials 34:9770–8
- Zhang X, Liu J, Ye F, et al. (2014). Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: a possible role of cytochrome P3A4 inhibition. Chin J Integ Med 20:534–9
- Zhou N, Zheng Y, Xing J, et al. (2016). Application of a new dynamic model to predict the in vitro intrinsic clearance of tolbutamide using rat microsomes encapsulated in a fab hydrogel. Drug Metab Dispos 44:40–9
- Zuegge J, Schneider G, Coassolo P, et al. (2001). Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin Pharmacokinet 40:553–63